Current and potential uses of imiquimod

被引:56
作者
Chang, YC
Madkan, V
Cook-Norris, R
Sra, K
Tyring, S
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77030 USA
[3] Ctr Clin Studies, Houston, TX USA
[4] Texas Tech Univ, Sch Med, Lubbock, TX 79409 USA
[5] Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77550 USA
关键词
imiquimod; immune response modifier; antiviral; antitumor;
D O I
10.1097/01.SMJ.0000176712.01491.98
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Imiquimod, an imidazoquinoline amine, is an immune response modifier first FDA-approved for the treatment of external genital and perianal warts in 1997. Since its appearance on the market, its antiviral and antitumor properties have been used in the treatment of a variety of dermatologic conditions. In this review article, the basic mechanism of action of imiquimod, current FDA-approved and non-FDA-approved uses of imiquimod, and key points of medication application frequency, possible adverse effects, and use in combination therapy are discussed. Common skin conditions that may be eradicated with imiquimod are emphasized.
引用
收藏
页码:914 / 920
页数:7
相关论文
共 42 条
[11]   Herpes simplex virus type 2 in the United States, 1976 TO 1994 [J].
Fleming, DT ;
McQuillan, GM ;
Johnson, RE ;
Nahmias, AJ ;
Aral, SO ;
Lee, FK ;
StLouis, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (16) :1105-1111
[12]   Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies [J].
Geisse, J ;
Caro, I ;
Lindholm, J ;
Golitz, L ;
Stampone, P ;
Owens, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (05) :722-733
[13]  
Gilbert J, 2001, ARCH DERMATOL, V137, P1015
[14]   Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway [J].
Hemmi, H ;
Kaisho, T ;
Takeuchi, O ;
Sato, S ;
Sanjo, H ;
Hoshino, K ;
Horiuchi, T ;
Tomizawa, H ;
Takeda, K ;
Akira, S .
NATURE IMMUNOLOGY, 2002, 3 (02) :196-200
[15]   Topical imiquimod treatment for nodular basal cell carcinomas: An open-label series [J].
Huber, A ;
Huber, JD ;
Skinner, RB ;
Kuwahara, RT ;
Haque, R ;
Amonette, RA .
DERMATOLOGIC SURGERY, 2004, 30 (03) :429-430
[16]  
Joura EA, 2000, J REPROD MED, V45, P613
[17]   Treatment of granuloma annulare with topical 5% imiquimod cream [J].
Kuwahara, RT ;
Naylor, MF ;
Skinner, RB .
PEDIATRIC DERMATOLOGY, 2003, 20 (01) :90-90
[18]   Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials [J].
Lebwohl, M ;
Dinehart, MB ;
Whiting, D ;
Lee, PK ;
Tawfik, N ;
Jorizzo, J ;
Lee, JH ;
Fox, TL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (05) :714-721
[19]   Imiquimod 5% cream in the treatment of Bowen's disease [J].
Mackenzie-Wood, A ;
Kossard, S ;
de Launey, J ;
Wilkinson, B ;
Owens, ML .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (03) :462-470
[20]   Use of imiquimod cream 5% in the treatment of localized morphea [J].
Man, J ;
Dytoc, MT .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 (03) :166-169